ATE493444T1 - Intrazelluläre peptidabgabe - Google Patents
Intrazelluläre peptidabgabeInfo
- Publication number
- ATE493444T1 ATE493444T1 AT05810515T AT05810515T ATE493444T1 AT E493444 T1 ATE493444 T1 AT E493444T1 AT 05810515 T AT05810515 T AT 05810515T AT 05810515 T AT05810515 T AT 05810515T AT E493444 T1 ATE493444 T1 AT E493444T1
- Authority
- AT
- Austria
- Prior art keywords
- peptide delivery
- intracellular peptide
- cell
- methods
- cells
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61972904P | 2004-10-18 | 2004-10-18 | |
PCT/US2005/037638 WO2006044986A1 (en) | 2004-10-18 | 2005-10-17 | Intracellular peptide delivery |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE493444T1 true ATE493444T1 (de) | 2011-01-15 |
Family
ID=35781442
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT05810515T ATE493444T1 (de) | 2004-10-18 | 2005-10-17 | Intrazelluläre peptidabgabe |
Country Status (6)
Country | Link |
---|---|
US (1) | US7521415B2 (de) |
EP (1) | EP1812074B1 (de) |
JP (1) | JP4959570B2 (de) |
AT (1) | ATE493444T1 (de) |
DE (1) | DE602005025676D1 (de) |
WO (1) | WO2006044986A1 (de) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8062891B2 (en) | 2003-10-24 | 2011-11-22 | Gencia Corporation | Nonviral vectors for delivering polynucleotides to plants |
US20090208478A1 (en) * | 2003-10-24 | 2009-08-20 | Gencia Corporation | Transducible polypeptides for modifying metabolism |
US20090123468A1 (en) | 2003-10-24 | 2009-05-14 | Gencia Corporation | Transducible polypeptides for modifying metabolism |
US8507277B2 (en) | 2003-10-24 | 2013-08-13 | Gencia Corporation | Nonviral vectors for delivering polynucleotides |
WO2005056752A2 (en) | 2003-10-24 | 2005-06-23 | Gencia Corporation | Methods and compositions for delivering polynucleotides |
US8133733B2 (en) | 2003-10-24 | 2012-03-13 | Gencia Corporation | Nonviral vectors for delivering polynucleotides to target tissues |
EP2913057B1 (de) | 2008-07-24 | 2017-09-06 | Indiana University Research and Technology Corporation | Krebspeptidtherapeutika |
US8349308B2 (en) | 2010-03-26 | 2013-01-08 | Mersana Therapeutics, Inc. | Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof |
BR112013031819B1 (pt) | 2011-06-10 | 2022-05-03 | Mersana Therapeutics, Inc | Suporte polimérico, composição farmacêutica, composto, e, uso do suporte |
US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
HUE036640T2 (hu) | 2012-02-14 | 2018-07-30 | Univ California | Parakrin gének szisztémás bejuttatása és szabályozott expressziója szív és érrendszeri betegségekre és egyéb állapotokra |
CN103214672B (zh) * | 2013-04-03 | 2016-01-13 | 上海交通大学 | 一种低分子量pei衍生物及制备方法和应用 |
CN105813655B (zh) | 2013-10-11 | 2022-03-15 | 阿萨纳生物科技有限责任公司 | 蛋白-聚合物-药物缀合物 |
MX367851B (es) | 2013-10-11 | 2019-09-09 | Mersana Therapeutics Inc | Conjugados de proteína-polímero-fármaco. |
WO2015150914A2 (en) | 2014-04-03 | 2015-10-08 | The Regents Of The University Of California | Systemic delivery of virus vectors encoding urocortin-2 and related genes to treat diabetes-related cardiac dysfunction and congestive heart failure |
WO2017100125A1 (en) | 2015-12-10 | 2017-06-15 | The Regents Of The University Of California | Compositions and methods for treating or ameliorating neuroinflammation, neurodegeneration, neuropathic pain, and migraine |
US10391154B2 (en) | 2017-07-19 | 2019-08-27 | Leadiant Biosciences Ltd. | Compositions and methods for treating or ameliorating fibrosis, systemic sclerosis and scleroderma |
ES2949701T3 (es) | 2018-07-26 | 2023-10-02 | Cvie Therapeutics Ltd | Compuestos similares al 17beta-heterociclil-digitalis para el tratamiento de la insuficiencia cardíaca |
CA3130261A1 (en) | 2019-03-05 | 2020-09-10 | Windtree Therapeutics, Inc. | Istaroxime-containing intravenous formulation for the treatment of acute heart failure (ahf) |
EP3805243B1 (de) | 2019-10-09 | 2023-11-15 | Windtree Therapeutics, Inc. | Androstanderivate mit wirkung als reine oder vorwiegend reine stimulatoren von serca2a zur behandlung von herzversagen |
KR20230159847A (ko) | 2021-03-18 | 2023-11-22 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 염증성 또는 활성화된 세포를 표적으로 하고 염증성 상태 및 통증을 치료 또는 개선하기 위한 조성물 및 방법 |
WO2023205183A1 (en) | 2022-04-20 | 2023-10-26 | Windtree Therapeutics, Inc. | Istaroxime-containing intravenous formulation for the treatment of pre-cardiogenic shock and cardiogenic shock |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5811510A (en) * | 1995-04-14 | 1998-09-22 | General Hospital Corporation | Biodegradable polyacetal polymers and methods for their formation and use |
US7220414B2 (en) * | 2000-09-06 | 2007-05-22 | A.P. Pharma, Inc. | Degradable polyacetal polymers |
US7166575B2 (en) * | 2002-12-17 | 2007-01-23 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity |
US6878374B2 (en) | 2003-02-25 | 2005-04-12 | Nitto Denko Corporation | Biodegradable polyacetals |
US7048925B2 (en) | 2003-08-28 | 2006-05-23 | Nitto Denko Corporation | Acid-sensitive polyacetals and methods |
US7348453B2 (en) * | 2003-09-04 | 2008-03-25 | Mirus Bio Corporation | Labile linkage for compound delivery to a cell |
US7163677B2 (en) | 2003-10-24 | 2007-01-16 | Nitto Denko Corporation | Cationic polymers having degradable crosslinks |
US7446099B2 (en) * | 2004-02-27 | 2008-11-04 | Nitto Denko Corporation | Compositions and methods for biodegradable polymer-peptide mediated transfection |
-
2005
- 2005-10-17 EP EP05810515A patent/EP1812074B1/de not_active Not-in-force
- 2005-10-17 DE DE602005025676T patent/DE602005025676D1/de active Active
- 2005-10-17 AT AT05810515T patent/ATE493444T1/de not_active IP Right Cessation
- 2005-10-17 JP JP2007537032A patent/JP4959570B2/ja not_active Expired - Fee Related
- 2005-10-17 US US11/251,956 patent/US7521415B2/en not_active Expired - Fee Related
- 2005-10-17 WO PCT/US2005/037638 patent/WO2006044986A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
EP1812074B1 (de) | 2010-12-29 |
EP1812074A1 (de) | 2007-08-01 |
DE602005025676D1 (de) | 2011-02-10 |
WO2006044986A1 (en) | 2006-04-27 |
JP2008516611A (ja) | 2008-05-22 |
US7521415B2 (en) | 2009-04-21 |
US20060083737A1 (en) | 2006-04-20 |
JP4959570B2 (ja) | 2012-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE493444T1 (de) | Intrazelluläre peptidabgabe | |
DE602005021379D1 (de) | System und verfahren zur produktion von antikörpern in der pflanzenzellkultur | |
DK1525320T3 (da) | Fremgangsmåde til ekspression af rekombinant protein i CHO-celler | |
MX2010007729A (es) | Vectores de expresion de mamifero mejorados y uso de los mismos. | |
NZ592159A (en) | Means and methods for influencing the stability of antibody producing cells | |
DK1846974T3 (da) | Membran-elektrode samlinger til brændstofceller, deres fremstilling og anvendelse og brændstofceller indeholdende disse | |
UA92157C2 (ru) | Способ продуцирования гормона роста | |
WO2007092161A3 (en) | A direct cellular energy delivery system | |
CO6351809A2 (es) | Productos de altos titulos de anticuerpos | |
TR201900213T4 (tr) | Bir sürekli hücre kültüründe bir polipeptit veya ilişkin virüsün üretim metodu. | |
WO2007084364A8 (en) | Improved il-12 for expression in mammalian cells | |
WO2005087915A3 (en) | Use of ethanolamine for enhancing cell growth in membrane systems | |
WO2006116181A3 (en) | Regulatory t cell mediator proteins and uses thereof | |
WO2006066229A3 (en) | Elicitation of antibodies to self peptides by immunization with dendritic cells | |
DK1743029T3 (da) | Cellefremstilling | |
ATE336567T1 (de) | Zellkulturmedium | |
WO2009021163A3 (en) | Enhancing gene transfer | |
WO2006041651A3 (en) | Fuel sources, fuel cells and methods of operating fuel cells | |
AU2008232699A8 (en) | High expression clones of mammalian cells with fluorescent protein A or G | |
WO2005089509A3 (en) | High throughput assay systems and methods for identifying agents that alter expression of cellular proteins | |
WO2004078915A3 (en) | Cell culture | |
WO2004016743A3 (en) | Culturing anaplasma | |
NO20015494L (no) | Fremgangsmåte for dyrking av celler | |
SI2084529T1 (sl) | Stabilne celične linije in postopki za evaluacijo gastrointestinalne absorpcije kemikalij | |
EA200701000A1 (ru) | Культуральная среда для клеток млекопитающих, не содержащая сыворотки |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |